James M. Cleary

1991–2025 年に発表

97
論文数
18,567
被引用数
51
h 指数
90
i10 指数

被引用数

James M. Cleary の年別被引用数1992 年: 被引用 1 件1995 年: 被引用 1 件1997 年: 被引用 1 件1998 年: 被引用 1 件1999 年: 被引用 1 件2001 年: 被引用 1 件2002 年: 被引用 6 件2003 年: 被引用 5 件2004 年: 被引用 2 件2005 年: 被引用 3 件2006 年: 被引用 2 件2007 年: 被引用 3 件2008 年: 被引用 4 件2010 年: 被引用 3 件2011 年: 被引用 3 件2012 年: 被引用 7 件2013 年: 被引用 8 件2014 年: 被引用 29 件2015 年: 被引用 42 件2016 年: 被引用 62 件2017 年: 被引用 93 件2018 年: 被引用 154 件2019 年: 被引用 414 件2020 年: 被引用 684 件2021 年: 被引用 913 件2022 年: 被引用 1,087 件2023 年: 被引用 1,055 件2024 年: 被引用 1,741 件2025 年: 被引用 921 件2026 年: 被引用 44 件1993〜1994 年は被引用が無いため表示していません1996 年は被引用が無いため表示していません2000 年は被引用が無いため表示していません2009 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,624 件、この内訳の 23.9%中国: 引用元論文 2,051 件、この内訳の 18.7%イタリア: 引用元論文 605 件、この内訳の 5.5%日本: 引用元論文 567 件、この内訳の 5.2%ドイツ: 引用元論文 553 件、この内訳の 5%イギリス: 引用元論文 512 件、この内訳の 4.7%フランス: 引用元論文 414 件、この内訳の 3.8%スペイン: 引用元論文 348 件、この内訳の 3.2%カナダ: 引用元論文 308 件、この内訳の 2.8%韓国: 引用元論文 284 件、この内訳の 2.6%オランダ: 引用元論文 235 件、この内訳の 2.1%オーストラリア: 引用元論文 202 件、この内訳の 1.8%
0%23.9%その他 20.7%

分野

  • Medicine70.8%
  • Biochemistry, Genetics and Molecular Biology20.5%
  • Immunology and Microbiology3.9%
  • Engineering2.1%
  • Neuroscience1%
  • Nursing0.4%
  • その他1.3%

トピック

  • Cancer Immunotherapy and Biomarkers6.3%
  • Ferroptosis and cancer prognosis5.4%
  • Pancreatic and Hepatic Oncology Research3.9%
  • Gastric Cancer Management and Outcomes3.4%
  • Cancer Genomics and Diagnostics3.2%
  • Cholangiocarcinoma and Gallbladder Cancer Studies3.1%
  • その他74.7%

共著者

全論文

検索で開く
  1. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2021 被引用: 2,927

  2. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Cindy Hon, Yu Chen, William C. Hahn, Mitchell P. Levesque, John G. Doench, Michael E. Berens, Alykhan F. Shamji, Paul A. Clemons, Brent R. Stockwell, Stuart L. Schreiber - Nature 2017 被引用: 2,059

  3. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 被引用: 1,763

  4. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James M. McFarland, Ewa Sicińska, Tyler Jacks, Ryan J. Sullivan, Geoffrey I. Shapiro, Thomas E. Clancy, Kimberly Perez, Douglas A. Rubinson, Kimmie Ng, James M. Cleary, Lorin Crawford, Scott R. Manalis, Jonathan A. Nowak, Brian M. Wolpin, William C. Hahn, Andrew J. Aguirre, Alex K. Shalek - Cell 2021 被引用: 614

  5. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 被引用: 1,075

  6. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2022 被引用: 442

  7. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2021 被引用: 473

  8. Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 被引用: 1,431

  9. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lauren Keogh, María Anguiano, Lance Stapleton, Zhiheng Jia, Michal Barzily-Rokni, Israel Cañadas, Tran C. Thai, Marc R. Hammond, Raven Vlahos, Eric S. Wang, Hua Zhang, Shuai Li, Glenn J. Hanna, Wei Huang, Mai P. Hoang, Adriano Piris, Jean-Pierre Eliane, Anat Stemmer‐Rachamimov, Lisa Cameron, Mei-Ju Su, Parin Shah, Benjamin Izar, Manisha Thakuria, Nicole R. LeBoeuf, Guilherme Rabinowits, Viswanath Gunda, Sareh Parangi, James M. Cleary, Brian C. Miller, Shunsuke Kitajima, Rohit Thummalapalli, Benchun Miao, Thanh U. Barbie, Vivek Sivathanu, Joshua A. Wong, William G. Richards, Raphael Bueno, Charles H. Yoon, Juan J. Miret, Meenhard Herlyn, Levi A. Garraway, Eliezer M. Van Allen, Gordon J. Freeman, Paul T. Kirschmeier, Jochen H. Lorch, Patrick A. Ott, F. Stephen Hodi, Keith T. Flaherty, Roger D. Kamm, Genevieve M. Boland, Kwok‐Kin Wong, David Dornan, Cloud P. Paweletz, David A. Barbie - Cancer Discovery 2017 被引用: 585

  10. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Priya S. Hibshman, Amber M. Amparo, Connor J. Hennessey, Matthew G. Rees, Melissa M. Ronan, Jennifer A. Roth, Jens Brodbeck, Lorenzo Tomassoni, Basil Bakir, Nicholas D. Socci, Laura E. Herring, Natalie K. Barker, Junning Wang, James M. Cleary, Brian M. Wolpin, John A. Chabot, Michael D. Kluger, Gulam A. Manji, Kenneth Y. Tsai, Miroslav Sekulic, Stephen M. Lagana, Andrea Califano, Elsa Quintana, Zhengping Wang, Jacqueline A.M. Smith, Matthew Holderfield, David Wildes, Scott W. Lowe, Michael A. Badgley, Andrew J. Aguirre, Robert H. Vonderheide, Ben Z. Stanger, Timour Baslan, Channing J. Der, Mallika Singh, Kenneth P. Olive - Nature 2024 被引用: 175

  11. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2024 被引用: 216

  12. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Richard F. Dunne, Daniel T. Chang, Albert C. Koong, Aram F. Hezel, William C. Hahn, Alex K. Shalek, Andrew J. Aguirre, Jonathan A. Nowak, Brian M. Wolpin - Cancer Research 2022 被引用: 90

  13. Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma

    著者: , , , , , , , , , , , , , , , - The Oncologist 2014 被引用: 372

  14. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Janet E. Murphy, Kimmie Ng, Anuj Patel, Kimberly Perez, Michael H. Rosenthal, Douglas A. Rubinson, Marvin Ryou, Geoffrey I. Shapiro, Ewa Sicińska, Stuart G. Silverman, Rebecca J. Nagy, Richard B. Lanman, Deborah Knoerzer, Dean J. Welsch, Matthew B. Yurgelun, Charles S. Fuchs, Levi A. Garraway, Gad Getz, Jason L. Hornick, Bruce E. Johnson, Matthew H. Kulke, Robert J. Mayer, Jeffrey W. Miller, Paul B. Shyn, David A. Tuveson, Nikhil Wagle, Jen Jen Yeh, William C. Hahn, Ryan B. Corcoran, Scott L. Carter, Brian M. Wolpin - Cancer Discovery 2018 被引用: 369

  15. Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors

    著者: , , , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2020 被引用: 118

  16. Biomarker-Guided Development of DNA Repair Inhibitors

    著者: , , , - Molecular Cell 2020 被引用: 230

  17. Institutional implementation of clinical tumor profiling on an unselected cancer population

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , William C. Hahn, Philip W. Kantoff, David J. Kwiatkowski, Bruce E. Johnson, Matthew Meyerson, Levi A. Garraway, Geoffrey I. Shapiro, Barrett J. Rollins, Neal I. Lindeman, Laura E. MacConaill - JCI Insight 2016 被引用: 448

  18. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2023 被引用: 85

  19. Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anna M. Tassinari, Hatice D. Saatcioglu, Adriana E. Tron, Wilhelm Haas, Daniel P. Cahill, Samuel K. McBrayer, Robert T. Manguso, Nabeel Bardeesy - Science 2024 被引用: 89

  20. Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma

    著者: , , , , , , , , , , , - npj Precision Oncology 2022 被引用: 78

  21. A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alexander Spektor, Scott J. Rodig, F. Stephen Hodi, Jonathan D. Schoenfeld - Clinical Cancer Research 2021 被引用: 101

  22. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jonathan A. Nowak - Clinical Cancer Research 2022 被引用: 76

  23. A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors

    著者: , , , , , , , , , , , , , , , , , , , - npj Precision Oncology 2021 被引用: 74

  24. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2019 被引用: 284